Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share
Preferred stock, shares authorized (shares)
Preferred Stock, Shares Authorized
Preferred stock, shares issued (shares)
Preferred Stock, Shares Issued
Preferred stock, shares outstanding (shares)
Preferred Stock, Shares Outstanding
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Common stock, shares authorized (shares)
Common Stock, Shares Authorized
Common stock issued (shares)
Common Stock, Shares, Issued
Common stock outstanding (shares)
Common Stock, Shares, Outstanding
Accounting Policies [Abstract]
Revenue by Customer
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
Changes in Accumulated Other Comprehensive Income (Loss)
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants
Derivative Instruments and Hedging Activities Disclosure [Text Block]
Equity [Abstract]
Total Stock Options Outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Total Stock Options Outstanding, Beginning balance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Total Stock Options Outstanding, Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Total Stock Options Outstanding, Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period
Share based compensation arrangement by share-based payment award, options, vested, outstanding number of shares.
Total Stock Options Outstanding, Forfeited, Canceled (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Total Stock Options Outstanding, Ending balance (in shares)
Weighted Average Exercise Price per Share
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price per Share, Beginning balance (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted Average Exercise Price per Share, Granted (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted Average Exercise Price per Share, Vested (in dollars per share)
Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price
Weighted Average Exercise Price per Share, Forfeited, Canceled (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Weighted Average Exercise Price per Share, Ending balance (in dollars per share)
Statement of Comprehensive Income [Abstract]
Net loss including noncontrolling interests
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Other comprehensive loss:
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Unrealized gain (loss) on short-term investments
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax
Foreign currency translation adjustment
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Comprehensive loss including noncontrolling interests
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive loss attributable to noncontrolling interests
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
Comprehensive loss attributable to Cleveland BioLabs, Inc.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Recurring
Fair Value, Measurements, Recurring [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Level 1
Fair Value, Inputs, Level 1 [Member]
Level 2
Fair Value, Inputs, Level 2 [Member]
Level 3
Fair Value, Inputs, Level 3 [Member]
Liability Class [Axis]
Liability Class [Axis]
Fair Value by Liability Class [Domain]
Fair Value by Liability Class [Domain]
Warrants
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Assets:
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Short-term investments
Short-Term Investments, Fair Value Disclosure
Short-Term Investments, Fair Value Disclosure
Total assets
Derivative Asset, Current
Liabilities:
Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]
Accrued warrant liability
Derivative Liability, Current
Related Party Transactions [Abstract]
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Related Party [Axis]
Related Party [Axis]
Related Party [Domain]
Related Party [Domain]
R P C I
R P C I [Member]
R P C I.
Cleveland Clinic
Cleveland Clinic [Member]
Cleveland Clinic [Member]
Buffalo BioLabs
Buffalo BioLabs [Member]
Buffalo BioLabs.
Incuron
Incuron [Member]
Incuron, LLC.
GPI And Board Of Directors And Management
GPI And Board Of Directors And Management [Member]
GPI And Board Of Directors And Management [Member]
GPI
GPI [Member]
GPI [Member]
Related Party Transaction [Axis]
Related Party Transaction [Axis]
Related Party Transaction [Domain]
Related Party Transaction [Domain]
Sublease and Other Income
Sublease and Other Income [Member]
Sublease and Other Income [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Accrued expenses payable
Due to Related Parties, Current
Royalty or milestone payments paid
Royalty Expense
Research and development expense
Research and Development Expense
Sublease and other income received
Revenue from Related Parties
Accounts receivable related parties, gross
Accounts Receivable, Related Parties, Gross
Accounts Receivable, Related Parties, Gross
Accounts receivable related parties
Accounts Receivable, Related Parties
Consultant expenses
Consultant Fees
Consultant Fees
Accounts payable and accrued expenses
Accounts Payable and Accrued Liabilities, Current
Reclassification out of Accumulated Other Comprehensive Income [Table]
Reclassification out of Accumulated Other Comprehensive Income [Table]
Equity Components [Axis]
Equity Components [Axis]
Equity Component [Domain]
Equity Component [Domain]
Gains and losses on foreign exchange translations
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
AOCI Including Portion Attributable to Noncontrolling Interest [Abstract]
Beginning balance
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Other comprehensive income (loss) before reclassifications
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Amounts reclassified from accumulated other comprehensive loss
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax
Ending balance
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Tax Credit Carryforward [Table]
Tax Credit Carryforward [Table]
Investor
Investor [Member]
Income Tax Authority [Axis]
Income Tax Authority [Axis]
Income Tax Authority [Domain]
Income Tax Authority [Domain]
Domestic Tax Authority
Domestic Tax Authority [Member]
State and Local Jurisdiction
State and Local Jurisdiction [Member]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward [Axis]
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward, Name [Domain]
Expire in 2023
Expire Two Thousand Twenty Three [Member]
Expire 2023.
Expire in 2024
Expire Two Thousand Twenty Four [Member]
Expire 2024.
Expire in 2027
Expire Two Thousand Twenty Seven [Member]
Expire 2027.
Expire in 2022
Expire Two Thousand Twenty Two [Member]
Expire two thousand twenty two.
Prior To July 2015, Limited
Tax Credit Prior To July 2015, Limited [Member]
Tax Credit Prior To July 2015, Limited [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward [Line Items]
Income tax expense (benefit)
Income Tax Expense (Benefit)
Total operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards
Net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards, Domestic
Tax credit carryforwards
Deferred Tax Assets, Tax Credit Carryforwards
U.S. state net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Shares of common stock sold (in shares)
Sale of Stock, Number of Shares Issued in Transaction
Percent of company purchased
Percentage of Common Shares Owned by Investor
Percentage of common shares owned by investor.
Operating loss carryforwards subject to expiration
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
Investment Income [Table]
Investment Income [Table]
Investment Type [Axis]
Investment Type [Axis]
Investments [Domain]
Investments [Domain]
Certificates of Deposit
Certificates of Deposit [Member]
Net Investment Income [Line Items]
Net Investment Income [Line Items]
Short-term investments
Short-term Investments
Fair Value of Financial Instruments
Fair Value Disclosures [Text Block]
Fair Value Hierarchy for Financial Assets and Liabilities Measured on Recurring Basis
Fair Value, by Balance Sheet Grouping [Table Text Block]
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions
Schedule Of Share Based Payment Award Warrant Liability Valuation Assumptions Table [Table Text Block]
Schedule of share based payment award warrant liability valuation assumptions.
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Accrued Warrant Liability
Accrued Warrant Liability [Member]
Accrued warrant liability.
Assets or liabilities measured at fair value on a recurring basis
Asset And Liabilities Fair Value Disclosure
Asset and liabilities fair value disclosure.
Range in years
Fair Value Assumptions, Expected Term
Basis of Presentation and Consolidation
Organization Consolidation And Presentation Of Financial Statements Disclosure Policy [Policy Text Block]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Policy Text Block]
Recent Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Short-Term Investments
Marketable Securities, Policy [Policy Text Block]
Significant Customers and Accounts Receivable
Receivables, Policy [Policy Text Block]
Other Comprehensive Income (Loss)
Comprehensive Income, Policy [Policy Text Block]
Accounting for Stock-Based Compensation
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Income Taxes
Income Tax, Policy [Policy Text Block]
Earnings (Loss) per Share
Earnings Per Share, Policy [Policy Text Block]
Contingencies
Commitments and Contingencies, Policy [Policy Text Block]
Summary of Option Award Activity
Share-based Compensation, Stock Options, Activity [Table Text Block]
Summary of Outstanding Stock Options
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Award Type [Axis]
Award Type [Axis]
Equity Award [Domain]
Equity Award [Domain]
Options
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options Outstanding, Quantity (in shares)
Stock Options Outstanding, Weighted-average exercise price (in dollars per share)
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Stock Options Outstanding, Intrinsic value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Vested Stock Options, Quantity ( in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Vested Stock Options, Weighted-average exercise price ( in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Vested Stock Options, Weighted Average Remaining Contractual Term (in Years)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Vested Stock Options, Intrinsic value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Options Additional Information:
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options granted during period (in shares)
Total fair value of options vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Compensation cost not yet recognized related to non-vested stock options
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Stockholders' Equity
Stockholders' Equity Note Disclosure [Text Block]
Cash, cash equivalents, and short-term investments
Cash, Cash Equivalents, and Short-term Investments
Restricted cash
Restricted Cash and Cash Equivalents
Cash available for use
Cash and Cash Equivalents, at Carrying Value
Income Statement [Abstract]
Revenues:
Revenues [Abstract]
Grants and contracts
Contracts Revenue
Operating expenses:
Operating Expenses [Abstract]
Research and development
General and administrative
General and Administrative Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income (Loss)
Other income (expense):
Other Nonoperating Income (Expense) [Abstract]
Interest and other income
Other Nonoperating Income (Expense)
Foreign exchange gain (loss)
Foreign Currency Transaction Gain (Loss), before Tax
Change in value of warrant liability
Fair Value Adjustment of Warrants
Total other income (expense)
Nonoperating Income (Expense)
Net loss
Net loss attributable to noncontrolling interests
Net Income (Loss) Attributable to Noncontrolling Interest
Net loss attributable to Cleveland BioLabs, Inc.
Net Income (Loss) Attributable to Parent
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)
Earnings Per Share, Basic and Diluted
Weighted average number of shares used in calculating net loss per share, basic and diluted (shares)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Outstanding Warrants
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]
Plan Name [Axis]
Plan Name [Axis]
Plan Name [Domain]
Plan Name [Domain]
2006 Equity Incentive Plan (The Plan)
2006 Equity Incentive Plan (The Plan) [Member]
2006 Equity Incentive Plan (The Plan) [Member]
2013 ESPP Plan
2013 Employee Stock Purchase Plan (ESSP) [Member]
2013 Employee Stock Purchase Plan (ESSP)
Shares authorized for issuance (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Shares available for future awards (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Common stock shares reserved for issuance upon exercise of currently outstanding stock options (in shares)
Common Stock, Capital Shares Reserved for Future Issuance
Maximum amount of shares that can be awarded annually to single participant (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee
Contractual life of shares awarded, maximum
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Percentage of the total number of shares of common stock outstanding of the preceding year
Percentage Of Common Stock Outstanding Of Preceding Year
Percentage of common stock outstanding of preceding year.
Maximum amount of shares of common stock that employee can purchase per year (in shares)
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Limited Per Year
Share based compensation arrangement by share based payment award number of shares limited per year.
Maximum percentage of annual compensation that employee can use to purchase common stock shares
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate
Percent of fair market value that common stock can be purchased at
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Schedule of Subsidiary or Equity Method Investee [Table]
Schedule of Subsidiary or Equity Method Investee [Table]
Joint Venture, The Company And Everon Ownership In GPI
Joint Venture, The Company And Everon Ownership In GPI [Member]
Joint Venture, The Company And Everon Ownership In GPI [Member]
Genome Protection, Inc., GPI
Genome Protection, Inc. [Member]
Genome Protection, Inc. [Member]
Investment, Name [Axis]
Investment, Name [Axis]
Investment, Name [Domain]
Investment, Name [Domain]
BioLab 612
Bio Lab 612 [Member]
Bio lab 612.
Subsidiary or Equity Method Investee [Line Items]
Subsidiary or Equity Method Investee [Line Items]
Number of wholly-owned subsidiaries
Number Of Wholly Owned Subsidiaries
Number of wholly-owned subsidiaries.
Ownership percentage
Ownership Interest In Joint Venture, Percentage
Ownership Interest In Joint Venture, Percentage
ASSETS
Assets [Abstract]
Current assets:
Assets, Current [Abstract]
Cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Accounts receivable
Accounts Receivable, Net, Current
Other current assets
Other Assets, Current
Total current assets
Assets, Current
Equipment, net
Property, Plant and Equipment, Net
Other long-term assets
Other Assets, Noncurrent
Total assets
Assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities and Equity [Abstract]
Current liabilities:
Liabilities, Current [Abstract]
Accounts payable
Accounts Payable, Current
Accrued expenses
Accrued Liabilities, Current
Total current liabilities
Liabilities, Current
Non-current liabilities
Liabilities, Noncurrent
Total liabilities
Liabilities
Stockholders’ equity:
Stockholders' Equity Attributable to Parent [Abstract]
Preferred stock, $.005 par value; 1,000,000 shares authorized as of June 30, 2018 and December 31, 2017, respectively, 0 shares issued and outstanding as of June 30, 2018 and December 31, 2017
Preferred Stock, Value, Issued
Common stock, $.005 par value; 25,000,000 shares authorized as of June 30, 2018 and December 31, 2017, respectively, 11,298,239 and 11,279,834 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital, Common Stock
Other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Total Cleveland BioLabs, Inc. stockholders’ equity
Stockholders' Equity Attributable to Parent
Noncontrolling interest in stockholders’ equity
Stockholders' Equity Attributable to Noncontrolling Interest
Total stockholders’ equity
Total liabilities and stockholders’ equity
Liabilities and Equity
Stock Price (in dollars per share)
Share Price
Exercise Price (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Term in years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Volatility
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Annual rate of quarterly dividends
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Discount rate- bond equivalent yield
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization
Depreciation, Depletion and Amortization
Non-cash investment income
Noncash Investment Income
Noncash investment income.
Gain on equipment disposal
Gain (Loss) on Disposition of Property Plant Equipment
Change in value of warrant liability
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable and other current assets
Increase Decrease In Accounts Receivable And Other Current Assets
Increase decrease in accounts receivable and other current assets.
Other long-term assets
Increase (Decrease) in Other Noncurrent Assets
Accounts payable and accrued expenses
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Purchase of short-term investments
Payments to Acquire Held-to-maturity Securities
Sale of short-term investments
Proceeds from Sale of Held-to-maturity Securities
Purchase of equipment
Payments to Acquire Machinery and Equipment
Proceeds from sale of equipment
Proceeds from Sale of Machinery and Equipment
Net cash provided by investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Exercise of warrants
Proceeds from Warrant Exercises
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Effect of exchange rate change on cash and equivalents
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Increase (decrease) in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Cash paid during the period for interest
Interest Paid
Document And Entity Information [Abstract]
Document And Entity Information [Abstract]
Entity Registrant Name
Entity Registrant Name
Trading Symbol
Trading Symbol
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding (in shares)
Entity Common Stock, Shares Outstanding
Warrants and Rights Note Disclosure [Abstract]
Class of Warrant or Right [Table]
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Class of Warrant or Right [Line Items]
Exercise price (in dollars per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrants expiration period
Warrant Expiration Period
Warrant Expiration Period
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Significant Alliances and Related Parties
Related Party Transactions Disclosure [Text Block]
Statement [Table]
Statement [Table]
Class of Warrant or Right [Axis]
Class of Warrant or Right [Axis]
Class of Warrant or Right [Domain]
Class of Warrant or Right [Domain]
Series B Pre-funded Warrants
SeriesB pre-funded Warrants [Member]
Series B pre-funded Warrants [Member]
Statement [Line Items]
Statement [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Total (gains) or losses, realized and unrealized, included in earnings
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Issuances
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
Settlements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Ending balance
Realized gains or losses
Fair Value Measurement With Unobservable Inputs Realized Gains Or Losses
Fair value measurement with unobservable inputs realized gains or losses.
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark [Domain]
Sales Revenue, Services, Net
Sales Revenue, Services, Net [Member]
Accounts Receivable
Accounts Receivable [Member]
Customer [Axis]
Customer [Axis]
Customer [Domain]
Customer [Domain]
Department of Defense
US Department of Defense [Member]
US Department of Defense [Member]
Concentration Risk Type [Axis]
Concentration Risk Type [Axis]
Concentration Risk Type [Domain]
Concentration Risk Type [Domain]
Customer Concentration Risk
Customer Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Revenue, Major Customer [Line Items]
Concentration risk percentage
Concentration Risk, Percentage
Increase (decrease) in concentration risk percentage
Increase (Decrease) in Concentration Risk Percentage
Increase (Decrease) in Concentration Risk Percentage
Credit term
Credit Term
Credit Term
Statement of Stockholders' Equity [Abstract]
Common Stock
Common Stock [Member]
Treasury Stock
Treasury Stock [Member]
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent [Member]
Accumulated Deficit
Retained Earnings [Member]
Noncontrolling Interests
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance (shares)
Shares, Outstanding
Foreign currency translation
Ending balance (shares)
Number of Warrants
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Warrants Outstanding, Beginning Balance (in shares)
Class of Warrant or Right, Outstanding
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period
Forfeited, Canceled (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Number of Warrants Outstanding, Ending Balance (in shares)
Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)
Weighted Average Exercise Price, Granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted Average Exercise Price, Exercised (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value
Weighted Average Exercise Price, Forfeited, Canceled (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted Average Exercise Price, Outstanding, Ending Balance (in dollars per share)